Wire · opportunities
Pariglasgene Brecaparvovec-opnr Approved for Glycogen Storage Disease 1a
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
The FDA granted accelerated approval to pariglasgene brecaparvovec-opnr, a one-time liver-directed AAV8 gene therapy by Ultragenyx Pharmaceutical, for patients aged 8 and older with glycogen storage disease type Ia (GSD1a), based on a 31% reduction in daily cornstarch intake versus placebo.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now build or integrate gene therapies targeting rare metabolic diseases with regulatory proof points from Genglycos approval. This opens a pathway for new gene therapies to reach US patients through accelerated FDA routes, but confirmatory trials remain required.
◆ Coverage
1 source · 20 Aug 2026
◆ Related on Wire
◆ Topics